| Field | Row 1 |
|---|---|
| adsh | 0001641172-25-011033 |
| cik | 946644 |
| name | AIM IMMUNOTECH INC. |
| sic | 2836 |
| countryba | US |
| stprba | FL |
| cityba | OCALA |
| zipba | 32801 |
| bas1 | 2117 SW HIGHWAY 484 |
| bas2 | |
| baph | 352-448-7797 |
| countryma | US |
| stprma | FL |
| cityma | OCALA |
| zipma | 32801 |
| mas1 | 2117 SW HIGHWAY 484 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 520845822 |
| former | HEMISPHERX BIOPHARMA INC |
| changed | 19950614 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250515 |
| accepted | 2025-05-15 16:46:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | form10-q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001641172-25-011033 | 20250331 | Amortization Of Intangible Assets | 48000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Assets Current | 4176000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Assets Current | 2584000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -2144000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Common Stock Value | 72000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Costs And Expenses | 5774000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Finite Lived Intangible Assets Net | 2495000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Patents; | ||
| 0001641172-25-011033 | 20250331 | Finite Lived Intangible Assets Net | 94000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Trademarks; | ||
| 0001641172-25-011033 | 20241231 | Retained Earnings Accumulated Deficit | -426828000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Revenues | 40000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Stockholders Equity | -1322000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Other Operating Assets | USD | 1 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 62000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Liabilities And Stockholders Equity | 8608000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Manufacturing Costs | 10000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Marketable Securities Current | 1349000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; | ||
| 0001641172-25-011033 | 20250331 | Marketable Securities Current | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; | |||
| 0001641172-25-011033 | 20240331 | Net Cash Provided By Used In Investing Activities | -158000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Net Income Loss | -3705000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Operating Income Loss | -5734000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Operating Lease Right Of Use Asset | 618000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Other Nonoperating Income Expense | 81000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Authorized | 10000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | |||
| 0001641172-25-011033 | 20241231 | Prepaid Expense And Other Assets Current | 199000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Proceeds From Notes Payable | USD | 1 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20240331 | Proceeds From Sale And Maturity Of Marketable Securities | 50000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20230930 | Research And Development Expense | 30000.0000 | USD | 0 | us-gaap/2024 | Legal Entity= Alcami; | Alcami | |
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 1080000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 7000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Alcami; | Alcami | |
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Jubilant Hollister Stier; Type Of Arrangement= Research Consulting And Supply Agreements; | ||
| 0001641172-25-011033 | 20250331 | Stockholders Equity | -430533000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Shares New Issues | 4285401.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Shares Other | 0.0000 | shares | 1 | us-gaap/2024 | Equity Components= Warrant; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Cashless Exercise Of Warrants | USD | 1 | 0001641172-25-011033 | Equity Components= Additional Paid In Capital; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value New Issues | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Share Based Compensation | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20240331 | Abandonment Of Patent And Trademark Rights | USD | 1 | 0001641172-25-011033 | ||||
| 0001641172-25-011033 | 20250331 | Additional Paid In Capital | 426604000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Cash And Cash Equivalents At Carrying Value | 1701000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 3295000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Common Stock Shares Outstanding | 65526320.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Accounts Payable | 124000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Accrued Liabilities | 62000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Operating Lease Liability | -62000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Interest Expense | 124000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Liabilities | 9930000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Net Cash Provided By Used In Financing Activities | 660000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Operating Lease Liability Current | 239000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 3000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Amarex Clinical Research L L C; Type Of Arrangement= Pancreatic Cancer; | ||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 102000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Amarex Clinical Research L L C; Type Of Arrangement= Post C O V I D; | ||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 15000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Azenova Sales International; | AzenovaSalesInternational | |
| 0001641172-25-011033 | 20250331 | Retained Earnings Accumulated Deficit | -430533000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Revenues | 16000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20231231 | Stockholders Equity | 49000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20241231 | Stockholders Equity | -426828000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Shares New Issues | 243009.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Common Stock; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Shares Share Based Compensation | 424225.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20230430 | Stock Issued During Period Value New Issues | 3100000.0000 | USD | 0 | us-gaap/2024 | Legal Entity= Maxim Group L L C; Range= Minimum; Type Of Arrangement= Equity Distribution Agreement; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value New Issues | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value New Issues | 4000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Share Based Compensation | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20240331 | Unrealized Gain Loss On Marketable Investments | -73000.0000 | USD | 1 | 0001641172-25-011033 | |||
| 0001641172-25-011033 | 20240331 | Amortization Of Debt Discount Premium | 73000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240531 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Stock; Type Of Arrangement= Securities Purchase Agreement; | ||
| 0001641172-25-011033 | 20250331 | Common Stock Shares Issued | 72290030.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250430 | Common Stock Shares Outstanding | 72290030.0000 | shares | 0 | us-gaap/2024 | Subsequent Event Type= Subsequent Event; | ||
| 0001641172-25-011033 | 20250331 | Depreciation | 10000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Finite Lived Intangible Assets Net | 2594000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Operating Lease Liability | 60000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Other Receivables | 19000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Marketable Securities Current | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; | |||
| 0001641172-25-011033 | 20250331 | Net Cash Provided By Used In Investing Activities | 898000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Net Income Loss | -5817000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001641172-25-011033 | 20250331 | Net Income Loss | -3705000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001641172-25-011033 | 20250331 | Operating Income Loss | -3619000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Operating Lease Liability Noncurrent | 338000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Operating Lease Right Of Use Asset | 554000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | |||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 1951000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 90000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Azenova Sales International; | AzenovaSalesInternational | |
| 0001641172-25-011033 | 20241231 | Shares Outstanding | 65526320.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20250331 | Shares Outstanding | 72290030.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20241231 | Stockholders Equity | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Stockholders Equity | 426604000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Cashless Exercise Of Warrants | USD | 1 | 0001641172-25-011033 | ||||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Other | 2000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Share Based Compensation | 80000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Share Based Compensation | 80000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Share Based Compensation | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Share Based Compensation | 60000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Assets | 8608000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 5439000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20250331 | Common Stock Shares Authorized | 350000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Costs And Expenses | 3635000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Earnings Per Share Basic | -0.1200 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Earnings Per Share Diluted | -0.1200 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Finite Lived Intangible Assets Net | 2267000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Gain Loss On Investments | 27000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Accounts Receivable | -1184000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Liabilities And Stockholders Equity | 6248000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Marketable Securities Current | 1349000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Marketable Securities Current | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; | |||
| 0001641172-25-011033 | 20240331 | Net Income Loss | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Net Income Loss | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | |||
| 0001641172-25-011033 | 20241231 | Operating Lease Liability Noncurrent | 395000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Other Receivables Net Current | 19000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Payments To Acquire Intangible Assets | 50000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Payments To Acquire Intangible Assets | 56000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Authorized | 4000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Prepaid Expense And Other Assets Current | 318000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20190930 | Proceeds From Issuance Or Sale Of Equity | 7200000.0000 | USD | 0 | us-gaap/2024 | Legal Entity= Alliance Global Partners L L C; | AllianceGlobalPartnersLLC | |
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 10000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Alcami; | Alcami | |
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 105000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Amarex Clinical Research L L C; | AmarexClinicalResearchLLC | |
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 180000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Manufacturing And Engineering; | ||
| 0001641172-25-011033 | 20241231 | Stockholders Equity | 425440000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20240531 | Stock Issued During Period Shares New Issues | 5640958.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Class B Common Warrant; Type Of Arrangement= Securities Purchase Agreement; | ||
| 0001641172-25-011033 | 20240531 | Stock Issued During Period Shares New Issues | 5640958.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Stock; Type Of Arrangement= Securities Purchase Agreement; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Shares New Issues | 83334.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Common Stock; | ||
| 0001641172-25-011033 | 20250430 | Stock Issued During Period Shares New Issues | 4133859.0000 | shares | 0 | us-gaap/2024 | Type Of Arrangement= Employee Stock Purchase Plan; | ||
| 0001641172-25-011033 | 20201231 | Stock Issued During Period Shares Other | 8873960.0000 | shares | 4 | us-gaap/2024 | Equity Components= Warrant; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Cashless Exercise Of Warrants | USD | 1 | 0001641172-25-011033 | Equity Components= Retained Earnings; | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Committed Shares | USD | 1 | 0001641172-25-011033 | ||||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value New Issues | 15000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; Legal Entity= Atlas Sciences Llc; Type Of Arrangement= Purchase And Registration Rights Agreement; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value New Issues | 328000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Other | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Other | 448000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Share Based Compensation | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | |||
| 0001641172-25-011033 | 20250331 | Abandonment Of Patent And Trademark Rights | 335000.0000 | USD | 1 | 0001641172-25-011033 | |||
| 0001641172-25-011033 | 20250331 | Accounts Payable Current | 6944000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Amortization Of Intangible Assets | 49000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Cash And Cash Equivalents At Carrying Value | 898000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Common Stock Shares Issued | 65526320.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Common Stock Shares Outstanding | 72290030.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Earnings Per Share Basic | -0.0500 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Gain Loss On Investments | -92000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | General And Administrative Expense | 3815000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Other Operating Assets | -367000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Net Cash Provided By Used In Financing Activities | 2829000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Net Cash Provided By Used In Operating Activities | -4815000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Net Cash Provided By Used In Operating Activities | -2361000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Net Income Loss | -5817000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Net Income Loss | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | |||
| 0001641172-25-011033 | 20250331 | Net Income Loss | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | |||
| 0001641172-25-011033 | 20250331 | Operating Lease Liability Current | 234000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Other Noncash Income Expense | 67000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Shares Authorized | 10000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Proceeds From Sale And Maturity Of Marketable Securities | 1045000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20221231 | Research And Development Expense | 200000.0000 | USD | 0 | us-gaap/2024 | Legal Entity= Erasmus; Type Of Arrangement= Joint Clinical Study Agreement; | ||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 86000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Amarex Clinical Research L L C; Type Of Arrangement= Pancreatic Cancer; | ||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 1000000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Jubilant Hollister Stier; Type Of Arrangement= Research Consulting And Supply Agreements; | ||
| 0001641172-25-011033 | 20231231 | Shares Outstanding | 49102484.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240331 | Shares Outstanding | 50251933.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20231231 | Stockholders Equity | 10234000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20231231 | Stockholders Equity | -409508000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001641172-25-011033 | 20241231 | Stockholders Equity | 66000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20201231 | Stock Issued During Period Shares Other | 1870000.0000 | shares | 4 | us-gaap/2024 | Equity Components= Pre Funded Warrants; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Shares Other | 205000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Warrant; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Shares Other | 2054084.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Committed Shares | USD | 1 | 0001641172-25-011033 | Equity Components= Additional Paid In Capital; | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Committed Shares | USD | 1 | 0001641172-25-011033 | Equity Components= Retained Earnings; | |||
| 0001641172-25-011033 | 20230430 | Stock Issued During Period Value New Issues | 8500000.0000 | USD | 0 | us-gaap/2024 | Legal Entity= Maxim Group L L C; Type Of Arrangement= Equity Distribution Agreement; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value New Issues | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value New Issues | 656000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 70329869.0000 | shares | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 70329869.0000 | shares | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Accrued Liabilities Current | 639000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Amortization Of Debt Discount Premium | 64000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Assets | 6248000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1701000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20240331 | Depreciation | 9000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Accounts Receivable | USD | 1 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Accrued Liabilities | -540000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Increase Decrease In Other Receivables | USD | 1 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20250331 | Liabilities Current | 9767000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Manufacturing Costs | 8000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Marketable Securities Current | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; | |||
| 0001641172-25-011033 | 20240331 | Net Income Loss | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | |||
| 0001641172-25-011033 | 20250331 | Net Income Loss | USD | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Notes Payable Current | 1950000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Other Assets Noncurrent | 745000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Other Nonoperating Income Expense | 11000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Payments To Acquire Marketable Securities | 158000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Preferred Stock Stated Value Per Share | 1000.0000 | USD | 0 | 0001641172-25-011033 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20240331 | Proceeds From Issuance Or Sale Of Equity | 329000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Property Plant And Equipment Net | 98000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Repayment Of Debt Obligation With Shares | 421000.0000 | USD | 1 | 0001641172-25-011033 | |||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 521000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Amarex Clinical Research L L C; | AmarexClinicalResearchLLC | |
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 435000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Amarex Clinical Research L L C; Type Of Arrangement= Post C O V I D; | ||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 4000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Erasmus; Type Of Arrangement= Jjoint Clinical Study Agreement; | ||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 230000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Quality Control; | ||
| 0001641172-25-011033 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 40000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Share Based Compensation | 80000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Share Based Compensation | 60000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stockholders Equity | 50000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Share Csashless Exercise Of Warrants | 3272.0000 | shares | 1 | 0001641172-25-011033 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240531 | Stock Issued During Period Shares New Issues | 5640958.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Warrant; Type Of Arrangement= Securities Purchase Agreement; | ||
| 0001641172-25-011033 | 20240930 | Stock Issued During Period Shares New Issues | 4653036.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Committed Shares | USD | 1 | 0001641172-25-011033 | Equity Components= Common Stock; | |||
| 0001641172-25-011033 | 20200630 | Stock Issued During Period Value New Issues | 500000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Directors Officers And Employees; | ||
| 0001641172-25-011033 | 20230430 | Stock Issued During Period Value New Issues | 8500000.0000 | USD | 0 | us-gaap/2024 | Legal Entity= Maxim Group L L C; Range= Maximum; Type Of Arrangement= Equity Distribution Agreement; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value New Issues | 329000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value New Issues | 660000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Unrealized Gain Loss On Marketable Investments | 96000.0000 | USD | 1 | 0001641172-25-011033 | |||
| 0001641172-25-011033 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 49458023.0000 | shares | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Accrued Liabilities Current | 606000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Additional Paid In Capital | 425440000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 898000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -803000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Common Stock Shares Authorized | 350000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | General And Administrative Expense | 2545000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Accounts Payable | 561000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 119000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Interest Expense | 72000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Marketable Securities Current | 2276000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Other Assets Noncurrent | 1112000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Other Noncash Income Expense | -64000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Payments To Acquire Marketable Securities | 91000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Stated Value Per Share | 1000.0000 | USD | 0 | 0001641172-25-011033 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20240930 | Proceeds From Issuance Or Sale Of Equity | 1260000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Proceeds From Issuance Or Sale Of Equity | 660000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Proceeds From Notes Payable | 2500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Property Plant And Equipment Net | 108000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Repayment Of Debt Obligation With Shares | USD | 1 | 0001641172-25-011033 | ||||
| 0001641172-25-011033 | 20240331 | Research And Development Expense | 129000.0000 | USD | 1 | us-gaap/2024 | Legal Entity= Pharma Solutions; Type Of Arrangement= Master Service Agreement And Quality Agreement; | ||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 594000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Clinical Studies; | ||
| 0001641172-25-011033 | 20231231 | Stockholders Equity | 689000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001641172-25-011033 | 20231231 | Stockholders Equity | 419004000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20240331 | Stockholders Equity | 4826000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stockholders Equity | 689000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001641172-25-011033 | 20240331 | Stockholders Equity | 419412000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20250331 | Stockholders Equity | -3857000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Shares Committed Shares | 338600.0000 | shares | 1 | 0001641172-25-011033 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20190930 | Stock Issued During Period Shares New Issues | 1740550.0000 | shares | 0 | us-gaap/2024 | Legal Entity= Alliance Global Partners L L C; | AllianceGlobalPartnersLLC | |
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Cashless Exercise Of Warrants | USD | 1 | 0001641172-25-011033 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value New Issues | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value New Issues | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Other | 450000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Share Based Compensation | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Share Based Compensation | 60000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Share Based Compensation | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | |||
| 0001641172-25-011033 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 49458023.0000 | shares | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Accounts Payable Current | 6383000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Common Stock Value | 66000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Earnings Per Share Diluted | -0.0500 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Finite Lived Intangible Assets Net | 99000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Trademarks; | ||
| 0001641172-25-011033 | 20250331 | Finite Lived Intangible Assets Net | 2173000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Patents; | ||
| 0001641172-25-011033 | 20250331 | Liabilities | 10105000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Liabilities Current | 9535000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Marketable Securities Current | 2276000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; | ||
| 0001641172-25-011033 | 20241231 | Notes Payable Current | 2307000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20241231 | Other Receivables Net Current | USD | 0 | us-gaap/2024 | ||||
| 0001641172-25-011033 | 20241231 | Preferred Stock Shares Authorized | 250000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Junior Participating Preferred Stock; | ||
| 0001641172-25-011033 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Convertible Preferred Stock; | ||
| 0001641172-25-011033 | 20250331 | Research And Development Expense | 76000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Regulatory; | ||
| 0001641172-25-011033 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 16000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stockholders Equity | -415325000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001641172-25-011033 | 20241130 | Stockholders Equity | 6000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20250331 | Stockholders Equity | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Stockholders Equity | 72000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20150331 | Stock Issued During Period Shares New Issues | 2054084.0000 | shares | 1 | us-gaap/2024 | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Shares New Issues | 807577.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Cashless Exercise Of Warrants | USD | 1 | 0001641172-25-011033 | Equity Components= Common Stock; | |||
| 0001641172-25-011033 | 20240331 | Stock Issued During Period Value Committed Shares | USD | 1 | 0001641172-25-011033 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | |||
| 0001641172-25-011033 | 20250331 | Stock Issued During Period Value Other | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Amortization Of Debt Discount Premium | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Discount (Premium) | Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Proceeds From Issuance Or Sale Of Equity | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance or Sale of Equity | The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. |
| Abandonment Of Patent And Trademark Rights | 0001641172-25-011033 | 1 | 0 | monetary | D | D | Abandonment and expiration of patents and trademark rights | Abandonment of patent and trademark rights. |
| Gain Loss On Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Investments | Amount of realized and unrealized gain (loss) on investment. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Stock Issued During Period Shares Committed Shares | 0001641172-25-011033 | 1 | 0 | shares | D | Committed Shares, shares | Stock issued during period shares committed shares. | |
| Unrealized Gain Loss On Marketable Investments | 0001641172-25-011033 | 1 | 0 | monetary | D | D | Unrealized gain (loss) on marketable investments | |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Stock Issued During Period Value Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture | Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Stock Issued During Period Value Committed Shares | 0001641172-25-011033 | 1 | 0 | monetary | D | C | Committed Shares | Stock issued during period value committed shares. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Interest Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Payments To Acquire Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Intangible Assets | The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. |
| Proceeds From Notes Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Notes Payable | The cash inflow from a borrowing supported by a written promise to pay an obligation. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Increase Decrease In Other Operating Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets | Amount of increase (decrease) in operating assets classified as other. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Marketable Securities Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Marketable Securities, Current | Amount of investment in marketable security, classified as current. |
| Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale and Maturity of Marketable Securities | The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Repayment Of Debt Obligation With Shares | 0001641172-25-011033 | 1 | 0 | monetary | D | D | Repayment of debt obligation with shares | |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Other Noncash Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Stock Issued During Period Value Cashless Exercise Of Warrants | 0001641172-25-011033 | 1 | 0 | monetary | D | C | Cashless Exercise of Warrants | Stock issued during period value cashless exercise of warrants. |
| Costs And Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Costs and Expenses | Total costs of sales and operating expenses for the period. |
| Finite Lived Intangible Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Finite-Lived Intangible Assets, Net | Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Notes Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Notes Payable, Current | Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Stock Issued During Period Shares Other | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Other | Number of shares of stock issued attributable to transactions classified as other. | |
| Preferred Stock Stated Value Per Share | 0001641172-25-011033 | 1 | 0 | perShare | I | Preferred stock, stated value | Preferred stock stated value per share. | |
| Stock Issued During Period Share Csashless Exercise Of Warrants | 0001641172-25-011033 | 1 | 0 | shares | D | Cashless Exercise of Warrants, shares | Stock issued during period shares cashless exercise of warrants. | |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Increase Decrease In Other Receivables | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Receivables | Amount of increase (decrease) in receivables classified as other. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Depreciation | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation | The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Other Receivables Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Receivables, Net, Current | Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. |
| Payments To Acquire Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Manufacturing Costs | us-gaap/2024 | 0 | 0 | monetary | D | D | Manufacturing Costs | The aggregate costs incurred in the production of goods for sale. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Stock Issued During Period Shares Share Based Compensation | us-gaap/2024 | 0 | 0 | shares | D | Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture | Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). | |
| Stock Issued During Period Value Other | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Other | Value of shares of stock issued attributable to transactions classified as other. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001641172-25-011033 | 6 | 17 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0001641172-25-011033 | 2 | 9 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001641172-25-011033 | 2 | 10 | BS | 0 | H | Marketable Securities Current | us-gaap/2024 | Marketable investments | 0 |
| 0001641172-25-011033 | 2 | 11 | BS | 0 | H | Other Receivables Net Current | us-gaap/2024 | Other Receivables | 0 |
| 0001641172-25-011033 | 2 | 12 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001641172-25-011033 | 2 | 13 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001641172-25-011033 | 2 | 14 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0001641172-25-011033 | 2 | 15 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Right of use asset, net | 0 |
| 0001641172-25-011033 | 2 | 16 | BS | 0 | H | Finite Lived Intangible Assets Net | us-gaap/2024 | Patent and trademark rights, net | 0 |
| 0001641172-25-011033 | 2 | 17 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets | 0 |
| 0001641172-25-011033 | 2 | 18 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001641172-25-011033 | 2 | 21 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001641172-25-011033 | 2 | 22 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0001641172-25-011033 | 2 | 23 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Current portion of operating lease liability | 0 |
| 0001641172-25-011033 | 2 | 24 | BS | 0 | H | Notes Payable Current | us-gaap/2024 | Current portion of note payable, net | 0 |
| 0001641172-25-011033 | 2 | 25 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001641172-25-011033 | 2 | 27 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating lease liability | 0 |
| 0001641172-25-011033 | 2 | 28 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001641172-25-011033 | 2 | 29 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Notes 13 and 14) | 0 |
| 0001641172-25-011033 | 2 | 31 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred Stock, value | 0 |
| 0001641172-25-011033 | 6 | 18 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses | 0 |
| 0001641172-25-011033 | 2 | 32 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 72,290,030 and 65,526,320 as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001641172-25-011033 | 2 | 33 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001641172-25-011033 | 2 | 34 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001641172-25-011033 | 2 | 35 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders deficit | 0 |
| 0001641172-25-011033 | 2 | 36 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders deficit | 0 |
| 0001641172-25-011033 | 3 | 7 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value | 0 |
| 0001641172-25-011033 | 3 | 8 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized | 0 |
| 0001641172-25-011033 | 3 | 9 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued | 0 |
| 0001641172-25-011033 | 3 | 10 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding | 0 |
| 0001641172-25-011033 | 3 | 11 | BS | 1 | H | Preferred Stock Stated Value Per Share | 0001641172-25-011033 | Preferred stock, stated value | 0 |
| 0001641172-25-011033 | 3 | 12 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0001641172-25-011033 | 3 | 13 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0001641172-25-011033 | 3 | 14 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0001641172-25-011033 | 3 | 15 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0001641172-25-011033 | 4 | 2 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Clinical treatment programs US | 0 |
| 0001641172-25-011033 | 4 | 3 | IS | 0 | H | Revenues | us-gaap/2024 | Total Revenues | 0 |
| 0001641172-25-011033 | 4 | 5 | IS | 0 | H | Manufacturing Costs | us-gaap/2024 | Production costs | 0 |
| 0001641172-25-011033 | 4 | 6 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001641172-25-011033 | 4 | 7 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0001641172-25-011033 | 4 | 8 | IS | 0 | H | Costs And Expenses | us-gaap/2024 | Total Costs and Expenses | 0 |
| 0001641172-25-011033 | 4 | 9 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Operating loss | 0 |
| 0001641172-25-011033 | 4 | 10 | IS | 0 | H | Gain Loss On Investments | us-gaap/2024 | Gain (Loss) on investments | 0 |
| 0001641172-25-011033 | 4 | 11 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Interest and other income | 0 |
| 0001641172-25-011033 | 4 | 12 | IS | 0 | H | Interest Expense | us-gaap/2024 | Interest Expense and Other Finance Costs | 1 |
| 0001641172-25-011033 | 4 | 13 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net Loss | 0 |
| 0001641172-25-011033 | 4 | 14 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic loss per share | 0 |
| 0001641172-25-011033 | 4 | 15 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted loss per share | 0 |
| 0001641172-25-011033 | 4 | 16 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted average shares outstanding basic | 0 |
| 0001641172-25-011033 | 4 | 17 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted average shares outstanding diluted | 0 |
| 0001641172-25-011033 | 5 | 12 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0001641172-25-011033 | 5 | 13 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance, shares | 0 |
| 0001641172-25-011033 | 5 | 14 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Common Stock issuance, net of costs | 0 |
| 0001641172-25-011033 | 5 | 15 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Common Stock issuance, net of costs, shares | 0 |
| 0001641172-25-011033 | 5 | 16 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation | us-gaap/2024 | Equity based compensation | 0 |
| 0001641172-25-011033 | 5 | 17 | EQ | 0 | H | Stock Issued During Period Shares Share Based Compensation | us-gaap/2024 | Equity-based compensation, shares | 0 |
| 0001641172-25-011033 | 5 | 18 | EQ | 0 | H | Stock Issued During Period Value Other | us-gaap/2024 | Repayment of Debt with shares | 0 |
| 0001641172-25-011033 | 5 | 19 | EQ | 0 | H | Stock Issued During Period Shares Other | us-gaap/2024 | Repayment of Debt with Shares, shares | 0 |
| 0001641172-25-011033 | 5 | 20 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net comprehensive loss | 0 |
| 0001641172-25-011033 | 5 | 21 | EQ | 0 | H | Stock Issued During Period Value Cashless Exercise Of Warrants | 0001641172-25-011033 | Cashless Exercise of Warrants | 0 |
| 0001641172-25-011033 | 5 | 22 | EQ | 0 | H | Stock Issued During Period Share Csashless Exercise Of Warrants | 0001641172-25-011033 | Cashless Exercise of Warrants, shares | 0 |
| 0001641172-25-011033 | 5 | 23 | EQ | 0 | H | Stock Issued During Period Value Committed Shares | 0001641172-25-011033 | Committed Shares | 0 |
| 0001641172-25-011033 | 5 | 24 | EQ | 0 | H | Stock Issued During Period Shares Committed Shares | 0001641172-25-011033 | Committed Shares, shares | 0 |
| 0001641172-25-011033 | 5 | 25 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0001641172-25-011033 | 5 | 26 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance, shares | 0 |
| 0001641172-25-011033 | 6 | 2 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0001641172-25-011033 | 6 | 4 | CF | 0 | H | Depreciation | us-gaap/2024 | Depreciation of property and equipment | 0 |
| 0001641172-25-011033 | 6 | 5 | CF | 0 | H | Abandonment Of Patent And Trademark Rights | 0001641172-25-011033 | Abandonment and expiration of patents and trademark rights | 0 |
| 0001641172-25-011033 | 6 | 6 | CF | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of patent, trademark rights | 0 |
| 0001641172-25-011033 | 6 | 7 | CF | 0 | H | Amortization Of Debt Discount Premium | us-gaap/2024 | Amortization of Debt Discount and Other Expenses | 0 |
| 0001641172-25-011033 | 6 | 8 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2024 | Non-cash lease expense | 1 |
| 0001641172-25-011033 | 6 | 9 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Equity-based compensation | 0 |
| 0001641172-25-011033 | 6 | 10 | CF | 0 | H | Gain Loss On Investments | us-gaap/2024 | Loss (gain) on sale of marketable investments | 1 |
| 0001641172-25-011033 | 6 | 12 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Funds receivable from New Jersey net operating loss | 1 |
| 0001641172-25-011033 | 6 | 13 | CF | 0 | H | Increase Decrease In Other Receivables | us-gaap/2024 | Other receivables | 1 |
| 0001641172-25-011033 | 6 | 14 | CF | 0 | H | Increase Decrease In Other Operating Assets | us-gaap/2024 | Other assets | 1 |
| 0001641172-25-011033 | 6 | 15 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets and other non-current assets | 1 |
| 0001641172-25-011033 | 6 | 16 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Lease liability | 0 |
| 0001641172-25-011033 | 6 | 19 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001641172-25-011033 | 6 | 21 | CF | 0 | H | Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2024 | Proceeds from sale of marketable investments | 0 |
| 0001641172-25-011033 | 6 | 22 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2024 | Purchase of marketable investments | 1 |
| 0001641172-25-011033 | 6 | 23 | CF | 0 | H | Payments To Acquire Intangible Assets | us-gaap/2024 | (Purchase) abandonment of patent and trademark rights | 1 |
| 0001641172-25-011033 | 6 | 24 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash provided by (used in) investing activities | 0 |
| 0001641172-25-011033 | 6 | 26 | CF | 0 | H | Proceeds From Issuance Or Sale Of Equity | us-gaap/2024 | Proceeds from sale of stock, net of issuance costs | 0 |
| 0001641172-25-011033 | 6 | 27 | CF | 0 | H | Proceeds From Notes Payable | us-gaap/2024 | Proceeds from note payable, net of issuance costs | 0 |
| 0001641172-25-011033 | 6 | 28 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0001641172-25-011033 | 6 | 29 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash and cash equivalents | 0 |
| 0001641172-25-011033 | 6 | 30 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents at beginning of period | 0 |
| 0001641172-25-011033 | 6 | 31 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents at end of period | 0 |
| 0001641172-25-011033 | 6 | 33 | CF | 0 | H | Unrealized Gain Loss On Marketable Investments | 0001641172-25-011033 | Unrealized gain (loss) on marketable investments | 0 |
| 0001641172-25-011033 | 6 | 34 | CF | 0 | H | Repayment Of Debt Obligation With Shares | 0001641172-25-011033 | Repayment of debt obligation with shares | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |